Table 3.
Association Between Change in Lipids and Apolipoproteins and Change in CEC
| Placebo | Anacetrapib | |||
|---|---|---|---|---|
| Individual Lipoprotein | All Lipoproteins | Individual Lipoproteins | All Lipoproteins | |
| Standard β (P Value)* | Standard β (P Value)† | Standard β (P Value) | Standard β (P Value) | |
| ΔHDL‡ | 0.05 (0.39) | −0.01 (0.89) | 0.03 (0.64) | 0.08 (0.37) |
| ΔApoA‐I | 0.21 (0.003) | 0.21 (0.02) | −0.04 (0.48) | −0.09 (0.29) |
| ΔApoB | 0.26 (0.0002) | 0.16 (0.04) | 0.12 (0.09) | 0.17 (0.02) |
| ΔTriglycerides | 0.24 (0.0006) | 0.15 (0.053) | −0.05 (0.48) | −0.08 (0.27) |
ApoA‐I indicates apolipoprotein A‐I; and ApoB, apolipoprotein B.
a
A separate linear regression model was used for each set of change in lipoproteins adjusted for baseline cholesterol efflux capacity (CEC), sex, race, presence of diabetes mellitus, and type of statin.
b
For the combined model, all lipoproteins were included together in separate models.
c
ΔHigh‐density lipoprotein (HDL) is defined as 24‐week HDL adjusted for baseline values.